News
SALT LAKE CITY, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding ...
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating ...
Guidance remains unchanged, with management projecting "over $100 million in partnership inflows by the end of 2026" and targeting a cash burn below $390 million in 2026. The company anticipates a ...
Zacks Investment Research on MSN3d
Recursion Pharmaceuticals to Report Q2 Earnings: What's in the Cards?Recursion Pharmaceuticals RXRX, a TechBio company that decodes biology and chemistry to industrialize drug discovery, is ...
Zacks Investment Research on MSN1d
RXRX Q2 Loss Wider Than Expected, Revenues Rise Y/Y, Stock DownRecursion Pharmaceuticals RXRX reported a loss of 41 cents per share in the second quarter of 2025, wider than the Zacks ...
Find all the latest ProFootballTalk news, live coverage, videos, highlights, stats, predictions, and results right here on NBC Sports.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback